Top

Published in:

01-12-2013

Chromosomal instability and transcriptome dynamics in cancer

Authors: Joshua B. Stevens, Steven D. Horne, Batoul Y. Abdallah, Christine J. Ye, Henry H. Heng

Published in: Cancer and Metastasis Reviews | Issue 3-4/2013

Abstract

Whole transcriptome profiling has long been proposed as a method of identifying cancer-specific gene expression profiles. Indeed, a multitude of these studies have generated vast amounts of expression data for many types of cancer, and most have identified specific gene signatures associated with a given cancer. These studies however, often contradict with each other, and gene lists only rarely overlap, challenging clinical application of cancer gene signatures. To understand this issue, the biological basis of transcriptome dynamics needs to be addressed. Chromosome instability (CIN) is the main contributor to genome heterogeneity and system dynamics, therefore the relationship between CIN, genome heterogeneity, and transcriptome dynamics has important implications for cancer research. In this review, we discuss CIN and its effects on the transcriptome during cancer progression, specifically how stochastic chromosome change results in transcriptome dynamics. This discussion is further applied to metastasis and drug resistance both of which have been linked to multiple diverse molecular mechanisms but are in fact driven by CIN. The diverse molecular mechanisms that drive each process are linked to karyotypic heterogeneity through the evolutionary mechanism of cancer. Karyotypic change and the resultant transcriptome change alter network function within cells increasing the evolutionary potential of the tumor. Future studies must embrace this instability-induced heterogeneity in order to devise new research and treatment modalities that focus on the evolutionary process of cancer rather than the individual genes that are uniquely changed in each tumor. Care is also needed in evaluating results from experimental systems which measure average values of a population.

Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503–511.PubMedCrossRef

Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747–752.PubMedCrossRef

Rimm, D. L. (2000). Molecular biology in cytopathology: current applications and future directions. Cancer, 90, 1–9.PubMedCrossRef

van't Veer, L. J., Dai, H. Y., van de Vijver, M. J., He, Y. D. D., Hart, A. A. M., et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530–536.CrossRef

Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., et al. (2006). Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Nat Cancer Inst, 98, 1183–1192.PubMedCrossRef

Lehmann, T., & Wrzesinski, T. (2012). The molecular basis of adrenocortical cancer. Cancer Genet, 205, 131–137.PubMedCrossRef

Lucas, S. M., & Heath, E. I. (2012). Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers. Prostate Cancer, 2012, 640968.PubMedCrossRef

Simon, R., Radmacher, M. D., Dobbin, K., & McShane, L. M. (2003). Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. Journal of the National Cancer Institute, 95, 14–18.PubMedCrossRef

Ein-Dor, L., Zuk, O., & Domany, E. (2006). Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proceedings of the National Academy of Sciences of the United States of America, 103, 5923–5928.PubMedCrossRef

10.

Venet, D., Dumont, J. E., & Detours, V. (2011). Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Computational Biology, 7, e1002240.PubMedCrossRef

11.

Kitano, H. (2002). Systems biology: a brief overview. Science, 295, 1662–1664.PubMedCrossRef

12.

Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519–525.

13.

Brock, A., Chang, H., & Huang, S. (2009). Non-genetic heterogeneity—a mutation-independent driving force for the somatic evolution of tumours. Nature Reviews Genetics, 10, 336–342.PubMedCrossRef

14.

Yurov, Y. B., Iourov, I. Y., Monakhov, V. V., Soloviev, I. V., Vostrikov, V. M., et al. (2005). The variation of aneuploidy frequency in the developing and adult human brain revealed by an interphase FISH study. Journal of Histochemistry and Cytochemistry, 53, 385–390.PubMedCrossRef

15.

Heng, H. H. (2013). Biocomplexity: challenging reductionism. In J. P. Sturmberg & C. C. Martin (Eds.), Handbook on systems and complexity in health. London: Springer.

16.

Duncan, A. W., Hanlon Newell, A. E., Smith, L., Wilson, E. M., Olson, S. B., et al. (2012). Frequent aneuploidy among normal human hepatocytes. Gastroenterology, 142, 25–28.PubMedCrossRef

17.

Rehen, S. K., Yung, Y. C., McCreight, M. P., Kaushal, D., Yang, A. H., et al. (2005). Constitutional aneuploidy in the normal human brain. Journal Neurosci, 25, 2176–2180.CrossRef

18.

Iourov, I. Y., Vorsanova, S. G., & Yurov, Y. B. (2008). Chromosomal mosaicism goes global. Molecular Cytogen, 1, 26.CrossRef

19.

Stevens, J.B., Abdallah, B.Y., Horne, S.D., Liu, G., Bremer, S.W., et al. (2011). Genetic and epigenetic heterogeneity in cancer. encyclopedia of life sciences. New York: Wiley

20.

Heng, H. H., Stevens, J. B., Bremer, S. W., Liu, G., Abdallah, B. Y., et al. (2011). Evolutionary mechanisms and diversity in cancer. Advances in Cancer Research, 112, 217–253.PubMedCrossRef

21.

Heng, H. H., Liu, G., Stevens, J. B., Bremer, S. W., Ye, K. J., et al. (2010). Genetic and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy. Current Drug Targets, 11, 1304–1316.PubMedCrossRef

22.

Bielas, J. H., & Loeb, L. A. (2005). Quantification of random genomic mutations. Nature Methods, 2, 285–290.PubMedCrossRef

23.

Gao, C., Furge, K., Koeman, J., Dykema, K., Su, Y., et al. (2007). Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proceedings of the National Academy of Sciences of the United States of America, 104, 8995–9000.PubMedCrossRef

24.

Tsafrir, D., Bacolod, M., Selvanayagam, Z., Tsafrir, I., Shia, J., et al. (2006). Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Research, 66, 2129–2137.PubMedCrossRef

25.

Cheng, L., Wang, P., Yang, S., Yang, Y., Zhang, Q., et al. (2012). Identification of genes with a correlation between copy number and expression in gastric cancer. BMC Medical Genomics, 5, 14.PubMedCrossRef

26.

Heng, H. H., Liu, G., Stevens, J. B., Bremer, S. W., Ye, K. J., et al. (2011). Decoding the genome beyond sequencing: the new phase of genomic research. Genomics, 98, 242–252.PubMedCrossRef

27.

Heng, H. H., Stevens, J. B., Liu, G., Bremer, S. W., Ye, K. J., et al. (2006). Stochastic cancer progression driven by non-clonal chromosome aberrations. Journal of Cellular Physiology, 208, 461–472.PubMedCrossRef

28.

Heng, H. H., Bremer, S. W., Stevens, J., Ye, K. J., Miller, F., et al. (2006). Cancer progression by non-clonal chromosome aberrations. Journal of Cellular Biochemistry, 98, 1424–1435.PubMedCrossRef

29.

Creekmore, A. L., Silkworth, W. T., Cimini, D., Jensen, R. V., Roberts, P. C., et al. (2011). Changes in gene expression and cellular architecture in an ovarian cancer progression model. PloS One, 6, e17676.PubMedCrossRef

30.

Lawrenson, L. (2010). Tracking profiles of genomic instability in spontaneous transformation and tumorigenesis. Detroit: Wayne State University School of Medicine.

31.

Okamura, K., Feuk, L., Marques-Bonet, T., Navarro, A., & Scherer, S. W. (2006). Frequent appearance of novel protein-coding sequences by frameshift translation. Genomics, 88, 690–697.PubMedCrossRef

32.

Nicke, B., Bastien, J., Khanna, S. J., Warne, P. H., Cowling, V., et al. (2005). Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. Molecular Cell, 20, 673–685.PubMedCrossRef

33.

Roberts, P. C., Mottillo, E. P., Baxa, A. C., Heng, H. H., Doyon-Reale, N., et al. (2005). Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model. Neoplasia, 7, 944–956.PubMedCrossRef

34.

Pavelka, N., Rancati, G., Zhu, J., Bradford, W. D., Saraf, A., et al. (2010). Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature, 468, 321–325.PubMedCrossRef

35.

Rancati, G., Pavelka, N., Fleharty, B., Noll, A., Trimble, R., et al. (2008). Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. Cell, 135, 879–893.PubMedCrossRef

36.

Springer, M., Weissman, J. S., & Kirschner, M. W. (2010). A general lack of compensation for gene dosage in yeast. Mol Sys Biol, 6, 368.

37.

Sheltzer, J. M., Torres, E. M., Dunham, M. J., & Amon, A. (2012). Transcriptional consequences of aneuploidy. Proceedings of the National Academy of Sciences, 109, 12644–12649.CrossRef

38.

FitzPatrick, D. R., Ramsay, J., McGill, N. I., Shade, M., Carothers, A. D., et al. (2002). Transcriptome analysis of human autosomal trisomy. Human Molecular Genetics, 11, 3249–3256.PubMedCrossRef

39.

Ait Yahya-Graison, E., Aubert, J., Dauphinot, L., Rivals, I., Prieur, M., et al. (2007). Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. American Journal of Human Genetics, 81, 475–491.PubMedCrossRef

40.

Stingele, S., Stoehr, G., Peplowska, K., Cox, J., Mann, M., et al. (2012). Global analysis of genome, transcriptome and proteome reveals the response to aneuploidy in human cells. Molecular Systems Biology, 8, 608.PubMedCrossRef

41.

Kuijjer, M. L., Rydbeck, H., Kresse, S. H., Buddingh, E. P., Lid, A. B., et al. (2012). Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes, Chromosomes & Cancer, 51, 696–706.CrossRef

42.

Huang, S. (2009). Non-genetic heterogeneity of cells in development: more than just noise. Development, 136, 3853–3862.PubMedCrossRef

43.

Chang, H. H., Hemberg, M., Barahona, M., Ingber, D. E., & Huang, S. (2008). Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature, 453, 544–547.PubMedCrossRef

44.

Ye, C. J., Stevens, J. B., Liu, G., Bremer, S. W., Jaiswal, A. S., et al. (2009). Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. Journal of Cellular Physiology, 219, 288–300.PubMedCrossRef

45.

Mi, R., Pan, C., Bian, X., Song, L., Tian, W., et al. (2012). Fusion between tumor cells enhances melanoma metastatic potential. Journal of Cancer Research and Clinical Oncology, 138, 1651–1658.PubMedCrossRef

46.

Pinto, A. E., Silva, G. L., Pereira, T., Cabrera, R. A., Santos, J. R., et al. (2012). S-phase fraction and ploidy as predictive markers in primary disease and recurrence of papillary thyroid carcinoma. Clinical Endocrinology, 77, 302–309.PubMedCrossRef

47.

Jasmine, F., Rahaman, R., Dodsworth, C., Roy, S., Paul, R., et al. (2012). A genome-wide study of cytogenetic changes in colorectal cancer using snp microarrays: opportunities for future personalized treatment. PloS One, 7, e31968.PubMedCrossRef

48.

Duesberg, P., Li, R., Fabarius, A., & Hehlmann, R. (2006). Aneuploidy and cancer: from correlation to causation. Contributions to Microbiology, 13, 16–44.PubMedCrossRef

49.

Braun, S., Auer, D., & Marth, C. (2009). The prognostic impact of bone marrow micrometastases in women with breast cancer. Cancer Investigation, 27, 598–603.PubMedCrossRef

50.

Habermann, J. K., Paulsen, U., Roblick, U. J., Upender, M. B., McShane, L. M., et al. (2007). Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes, Chromosomes & Cancer, 46, 10–26.CrossRef

51.

Lu, X., Lu, X., & Kang, Y. (2010). Organ-specific enhancement of metastasis by spontaneous ploidy duplication and cell size enlargement. Cell Research, 20, 1012–1022.PubMedCrossRef

52.

Adeyinka, A., Kytola, S., Mertens, F., Pandis, N., & Larsson, C. (2000). Spectral karyotyping and chromosome banding studies of primary breast carcinomas and their lymph node metastases. International Journal of Molecular Medicine, 5, 235–240.PubMed

53.

Popescu, N. C., & Zimonjic, D. B. (2002). Chromosome and gene alterations in breast cancer as markers for diagnosis and prognosis as well as pathogenetic targets for therapy. American Journal of Medical Genetics, 115, 142–149.PubMedCrossRef

54.

Bieche, I., & Lidereau, R. (1995). Genetic alterations in breast-cancer. Genes, Chromosomes & Cancer, 14, 227–251.CrossRef

55.

Goodison, S., Viars, C., & Urquidi, V. (2005). Molecular cytogenetic analysis of a human breast metastasis model: identification of phenotype-specific chromosomal rearrangements. Cancer Genetics and Cytogenetics, 156, 37–48.PubMedCrossRef

56.

Klein, C. A., Blankenstein, T. J., Schmidt-Kittler, O., Petronio, M., Polzer, B., et al. (2002). Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet, 360, 683–689.PubMedCrossRef

57.

Malkhosyan, S., Yasuda, J., Soto, J. L., Sekiya, T., Yokota, J., et al. (1998). Molecular karyotype (amplotype) of metastatic colorectal cancer by unbiased arbitrarily primed PCR DNA fingerprinting. Proceedings of the National Academy of Sciences of the United States of America, 95, 10170–10175.PubMedCrossRef

58.

Barbazan, J., Alonso-Alconada, L., Muinelo-Romay, L., Vieito, M., Abalo, A., et al. (2012). Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PloS One, 7, e40476.PubMedCrossRef

59.

Gupta, G. P., Nguyen, D. X., Chiang, A. C., Bos, P. D., Kim, J. Y., et al. (2007). Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature, 446, 765–770.PubMedCrossRef

60.

Lunt, S. J., Chaudary, N., & Hill, R. P. (2009). The tumor microenvironment and metastatic disease. Clinical & Experimental Metastasis, 26, 19–34.CrossRef

61.

Ellsworth, R., Ellsworth, D., Patney, H., Deyarmin, B., Hooke, J., et al. (2008). Genomic alterations associated with early stages of breast tumor metastasis. Annals of Surgical Oncology, 15, 1989–1995.PubMedCrossRef

62.

Heng, H.H., Bremer, S.W., Stevens, J.B., Horne, S.D., Liu, G., et al. (2013). Chromosomal instability (CIN): what is it and why it is crucial to cancer evolution. Cancer and Metastasis Reviews (in press).

63.

Sethi, N., & Kang, Y. (2011). Unravelling the complexity of metastasis—molecular understanding and targeted therapies. Nature Reviews Cancer, 11, 735–748.PubMedCrossRef

64.

Frost, P., Kerbel, R. S., Hunt, B., Man, S., & Pathak, S. (1987). Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2′-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression. Cancer Research, 47, 2690–2695.PubMed

65.

Ince, T. A., Richardson, A. L., Bell, G. W., Saitoh, M., Godar, S., et al. (2007). Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell, 12, 160–170.PubMedCrossRef

66.

Ton, N. C., & Jayson, G. C. (2004). Resistance to anti-VEGF agents. Current Pharmaceutical Design, 10, 51–64.PubMedCrossRef

67.

Horne, S.D., Stevens, J.B., Abdallah, B.Y., Liu, G., Bremer, S.W., et al. (2013). Why Gleevec remains the exception of cancer research—a genome-based evolutionary perspective. Journal of Cellular Physiology 228:665–670

68.

Higgins, C. F. (2007). Multiple molecular mechanisms for multidrug resistance transporters. Nature, 446, 749–757.PubMedCrossRef

69.

Duesberg, P., Stindl, R., & Hehlmann, R. (2001). Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proceedings of the National Academy of Sciences of the United States of America, 98, 11283–11288.PubMedCrossRef

70.

Heng, H.H., Liu, G., Stevens, J.B., Abdallah, B.Y., Horne, S.D., et al. (2013). Karyotype heterogeneity and unclassified chromosomal abnormalities. Cytogenetic and Genome Research, 2, 144–157.

71.

Forment, J. V., Kaidi, A., & Jackson, S. P. (2012). Chromothripsis and cancer: causes and consequences of chromosome shattering. Nature Reviews Cancer, 12, 663–670.PubMedCrossRef

72.

Foraker, A. B., Camus, S. M., Evans, T. M., Majeed, S. R., Chen, C.-Y., et al. (2012). Clathrin promotes centrosome integrity in early mitosis through stabilization of centrosomal ch-TOG. The Journal of Cell Biology, 198, 591–605.PubMedCrossRef

73.

Maher, C. A., Palanisamy, N., Brenner, J. C., Cao, X., Kalyana-Sundaram, S., et al. (2009). Chimeric transcript discovery by paired-end transcriptome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 106, 12353–12358.PubMedCrossRef

74.

Maher, J., Brentjens, R. J., Gunset, G., Riviere, I., & Sadelain, M. (2002). Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR[ζ]/CD28 receptor. Nature Biotechnology, 20, 70–75.PubMedCrossRef

75.

Blount, Z. D., Barrick, J. E., Davidson, C. J., & Lenski, R. E. (2012). Genomic analysis of a key innovation in an experimental Escherichia coli population. Nature, 489, 513–518.PubMedCrossRef

76.

Heng, H. H. (2009). The genome-centric concept: resynthesis of evolutionary theory. Bioessays, 31, 512–525.PubMedCrossRef

77.

Gillies, R. J., Verduzco, D., & Gatenby, R. A. (2012). Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nature Reviews Cancer, 12, 487–493.PubMedCrossRef

78.

Heng, H.H. (2013). 4-D Genomics: genome dynamics and constraint in evolution: New York: Springer

Title: Chromosomal instability and transcriptome dynamics in cancer
Authors: Joshua B. Stevens
Steven D. Horne
Batoul Y. Abdallah
Christine J. Ye
Henry H. Heng
Publication date: 01-12-2013
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 3-4/2013
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-013-9428-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2013

Functions, divergence and clinical value of TAp73 isoforms in cancer

Biography—Henry H.Q. Heng

Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution

Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?

Erratum to: The role of FOXP3 in the development and metastatic spread of breast cancer

Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer